» Articles » PMID: 25758675

MRI Phenotype of Breast Cancer: Kinetic Assessment for Molecular Subtypes

Overview
Date 2015 Mar 12
PMID 25758675
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate the dynamic contrast-enhanced magnetic resonance imaging (MRI) kinetic characteristics of newly diagnosed breast cancer molecular subtypes.

Materials And Methods: Breast MRI examinations of 112 patients with newly diagnosed breast cancer were reviewed. Cases of newly diagnosed invasive ductal carcinoma were sorted by molecular subtype (28 TN, 11 HER2 +, 73 Lum A/B) and MRI field strength, with lesion segmentation and kinetic analyses performed on a dedicated workstation. For kinetic assessment, 50% and 100% thresholds were employed for display of medium and rapid uptake. Kinetic profiles in terms of percent volume for six kinetic types (medium-persistent, medium-plateau, medium-washout, fast-persistent, fast-plateau, fast-washout) relative to the whole volume of the lesion were obtained. Statistical analysis of the kinetic profiles was performed using Welch's t-test.

Results: Percent volume of HER2-positive lesions with >100% uptake at early phase on 3T strength MRI exams was significantly greater compared with luminal A/B (93.8 ± 0.92 vs. 77.3 ± 7.2; P < 0.01) and triple negative (93.8 ± 0.92 vs. 81.3 ± 8.2; P < 0.05) subtypes. The >50% early phase uptake for HER2+ lesions was also higher than Lum A/B (99.1 ± 0.73 vs. 93.6 ± 3.05; P < 0.01) at 3T. In the 1.5T subgroup the percent volume of HER2+ tumors with >50% and >100% early phase uptake trended higher than Lum A/B lesions without reaching significance.

Conclusion: The percent volume of HER2-positive tumors demonstrating rapid early contrast uptake is significantly increased compared to other molecular subtypes.

Citing Articles

[Importance of parametric and molecular imaging for therapeutic management of breast cancer].

Hack C, Wetzl M, Schmidt D, Beckmann M Radiologie (Heidelb). 2024; 65(3):154-161.

PMID: 39643699 DOI: 10.1007/s00117-024-01394-x.


Whole tumour- and subregion-based radiomics of contrast-enhanced mammography in differentiating HER2 expression status of invasive breast cancers: A double-centre pilot study.

Wang S, Wang T, Guo S, Zhu S, Chen R, Zheng J Br J Cancer. 2024; 131(10):1613-1622.

PMID: 39379571 PMC: 11554679. DOI: 10.1038/s41416-024-02871-9.


The association of magnetic resonance imaging features with five molecular subtypes of breast cancer.

Nguyen V, Duong D, Nguyen Q, Nguyen D, Tran T, Duong T Eur J Radiol Open. 2024; 13:100585.

PMID: 39041054 PMC: 11261403. DOI: 10.1016/j.ejro.2024.100585.


Development and validation of machine learning models for predicting HER2-zero and HER2-low breast cancers.

Huang X, Wu L, Liu Y, Xu Z, Liu C, Liu Z Br J Radiol. 2024; 97(1161):1568-1576.

PMID: 38991838 PMC: 11332671. DOI: 10.1093/bjr/tqae124.


Predicting Malignancy of Breast Imaging Findings Using Quantitative Analysis of Contrast-Enhanced Mammography (CEM).

Miller M, Rubaiyat A, Rohde G Diagnostics (Basel). 2023; 13(6).

PMID: 36980437 PMC: 10047016. DOI: 10.3390/diagnostics13061129.